Published in Clin Exp Obstet Gynecol on January 01, 1990
Research priorities in biomarkers and surrogate end-points. Br J Clin Pharmacol (2012) 0.91
Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med (1976) 9.68
Comparing radical mastectomy with quadrantectomy, axillary dissection, and radiotherapy in patients with small cancers of the breast. N Engl J Med (1981) 7.53
Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer (1975) 2.52
Clinical evaluation of adriamycin, a new antitumour antibiotic. Br Med J (1969) 1.89
Insulin and gall stones: a population case control study in southern Italy. Gut (2000) 1.60
Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small-cell lung cancer. J Clin Oncol (2000) 1.59
Radiofrequency thermal ablation of 69 lung neoplasms. J Chemother (2004) 1.58
A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer. Eur J Cancer (1998) 1.55
Phase I and preliminary phase II evaluation of adriamycin (NSC 123127). Cancer Res (1970) 1.50
Are surgical adjuvant trials altering the course of breast cancer? Semin Oncol (1978) 1.49
Phase II study of intensive CEV (carboplatin, epirubicin and VP-16) plus G-CSF (granulocyte-colony stimulating factor) in extensive small cell lung cancer. Eur J Cancer (1995) 1.42
Detection of haemagglutinin D222 polymorphisms in influenza A(H1N1)pdm09-infected patients by ultra-deep pyrosequencing. Clin Microbiol Infect (2012) 1.41
cAMP-dependent phosphorylation of the nuclear encoded 18-kDa (IP) subunit of respiratory complex I and activation of the complex in serum-starved mouse fibroblast cultures. J Biol Chem (2000) 1.33
Adriamycin plus vincristine compared to and combined with cyclophosphamide, methotrexate, and 5-fluorouracil for advanced breast cancer. Cancer (1975) 1.31
Biomarkers predictive for clinical efficacy of taxol-based chemotherapy in advanced breast cancer. Ann Oncol (2005) 1.22
Combined chemotherapy-radiotherapy approach in locally advanced (T3b-T4) breast cancer. Cancer Chemother Pharmacol (1978) 1.22
Treatment of triple negative breast cancer (TNBC): current options and future perspectives. Cancer Treat Rev (2010) 1.19
Multimodal treatment for locally advanced breast cancer. Result of chemotherapy-radiotherapy versus chemotherapy-surgery. Cancer Clin Trials (1981) 1.17
Safety, tolerance, biodistribution, and MR imaging enhancement of the liver with gadobenate dimeglumine: results of clinical pharmacologic and pilot imaging studies in nonpatient and patient volunteers. Acad Radiol (1999) 1.17
Response and survival in advanced breast cancer after two non-cross-resistant combinations. Br Med J (1976) 1.16
Prevention of endemic canine vector-borne diseases using imidacloprid 10% and permethrin 50% in young dogs: a longitudinal field study. Vet Parasitol (2010) 1.16
Thymidilate synthase and p53 primary tumour expression as predictive factors for advanced colorectal cancer patients. Br J Cancer (2000) 1.11
Inhibition of HIV type 1 BaL replication by MIP-1alpha, MIP-1beta, and RANTES in macrophages. AIDS Res Hum Retroviruses (1998) 1.10
Metastatic malignant melanoma of the gallbladder: a case report and review of the literature. Melanoma Res (2002) 1.09
Gadolinium chelates with weak binding to serum proteins. A new class of high-efficiency, general purpose contrast agents for magnetic resonance imaging. Invest Radiol (1997) 1.09
Cyclic adenosine monophosphate-dependent phosphorylation of mammalian mitochondrial proteins: enzyme and substrate characterization and functional role. Biochemistry (2001) 1.08
Cell kinetics and hormonal receptor status in inflammatory breast carcinoma. Comparison with locally advanced disease. Cancer (1989) 1.06
Inflammatory cancer of the breast: analysis of 114 cases. J Surg Oncol (1981) 1.05
Multihance clinical pharmacology: biodistribution and MR enhancement of the liver. Acad Radiol (1998) 1.05
Gemcitabine plus vinorelbine yields better survival outcome than vinorelbine alone in elderly patients with advanced non-small cell lung cancer. A Southern Italy Cooperative Oncology Group (SICOG) phase III trial. Lung Cancer (2001) 1.02
HIV type 1 grown on interferon gamma-treated U937 cells shows selective increase in virion-associated intercellular adhesion molecule 1 and HLA-DR and enhanced infectivity for CD4-negative cells. AIDS Res Hum Retroviruses (1995) 1.01
A phase II randomized multicenter trial of gefitinib plus FOLFIRI and FOLFIRI alone in patients with metastatic colorectal cancer. Ann Oncol (2008) 0.99
[Clinical trials with adriamycin in leukemia and solid tumors]. Tumori (1969) 0.98
Molecular mechanisms for the hepatic uptake of magnetic resonance imaging contrast agents. Biochem Biophys Res Commun (1999) 0.98
KEYnet: a keywords database for biosequences functional organization. Nucleic Acids Res (1999) 0.97
Characterization of the murine orthologue of a novel human subtelomeric multigene family. Cytogenet Cell Genet (2001) 0.95
Paclitaxel, cisplatin and lonidamine in advanced ovarian cancer. A phase II study. Eur J Cancer (2001) 0.95
Cellular labeling with Gd(III) chelates: only high thermodynamic stabilities prevent the cells acting as 'sponges' of Gd3+ ions. Contrast Media Mol Imaging (2006) 0.94
Helicobacter pylori is associated with modified lipid profile: impact on Lipoprotein(a). Clin Biochem (2003) 0.93
Cisplatin, gemcitabine, and vinorelbine combination therapy in advanced non-small-cell lung cancer: a phase II randomized study of the Southern Italy Cooperative Oncology Group. J Clin Oncol (1999) 0.92
p53 and PCNA expression in advanced colorectal cancer: response to chemotherapy and long-term prognosis. Int J Cancer (1996) 0.92
Cost of skeletal-related events in European patients with solid tumours and bone metastases: data from a prospective multinational observational study. J Med Econ (2013) 0.92
Ovarian fibroma: our experience of 34 cases. Eur J Gynaecol Oncol (2003) 0.92
MMP-2, MMP-9, VEGF and CA 15.3 in breast cancer. Anticancer Res (2007) 0.91
Clinical trials with bleomycin in lymphomas and in solid tumors. Eur J Cancer (1972) 0.90
Phase I/II study of gemcitabine plus vinorelbine as first-line chemotherapy of non-small-cell lung cancer. J Clin Oncol (2000) 0.90
Epithelial ovarian cancer: second and third line chemotherapy (review). Int J Oncol (2002) 0.89
Salvage treatment after r-interferon alpha-2a in advanced neuroendocrine tumors. Acta Oncol (1993) 0.89
A prospective observational study to evaluate G-CSF usage in patients with solid tumors receiving myelosuppressive chemotherapy in Italian clinical oncology practice. Med Oncol (2013) 0.89
Relationship among fatty liver, adipose tissue distribution and metabolic profile in moderately obese children: an ultrasonographic study. Curr Pharm Des (2008) 0.89
Liposomal-encapsulated doxorubicin plus cyclophosphamide as first-line therapy in metastatic breast cancer: a phase II multicentric study. Ann Oncol (2007) 0.89
Gemcitabine plus cisplatin for advanced transitional cell carcinoma of the urinary tract: a phase II multicenter trial. J Urol (2000) 0.89
Ovarian bilateral cystic teratomas: diagnosis and therapy in a young woman. Clin Exp Obstet Gynecol (1990) 0.89
Effects of the human CD38 glycoprotein on the early stages of the HIV-1 replication cycle. FASEB J (1999) 0.89
Vascular endothelial growth factor enhances in vitro proliferation and osteogenic differentiation of human dental pulp stem cells. J Biol Regul Homeost Agents (2011) 0.88
Cisplatin, gemcitabine, and paclitaxel in locally advanced or metastatic non-small-cell lung cancer: a phase I-II study. Southern Italy Cooperative Oncology Group. J Clin Oncol (1999) 0.88
Serum 90K/MAC-2BP glycoprotein in patients with liver cirrhosis and hepatocellular carcinoma: a comparison with alpha-fetoprotein. Clin Chem Lab Med (2001) 0.88
Adriamycin versus adriamycin plus melphalan in advanced ovarian carcinoma. Cancer Treat Rep (1977) 0.87
Relationship between cytosol TPS, TPA and cell proliferation. Int J Biol Markers (1994) 0.87
Serum 90K/MAC-2BP glycoprotein levels in hepatocellular carcinoma and cirrhosis. Anticancer Res (2000) 0.87
Abc protein transport of MRI contrast agents in canalicular rat liver plasma vesicles and yeast vacuoles. Biochem Biophys Res Commun (2001) 0.87
Heterogeneity of intratumour proliferative activity in primary breast cancer: biological and clinical aspects. Eur J Cancer (1995) 0.86
Phase II study of gemcitabine plus oxaliplatin as first-line chemotherapy for advanced non-small-cell lung cancer. Br J Cancer (2005) 0.86
Mixed micelles containing lipophilic gadolinium complexes as MRA contrast agents. MAGMA (2001) 0.86
Combination chemotherapy and combined treatment modality in disseminated and locally advanced breast cancer. Prog Clin Biol Res (1977) 0.85
Oxaliplatin plus raltitrexed and leucovorin-modulated 5-fluorouracil i.v. bolus: a salvage regimen for colorectal cancer patients. Br J Cancer (2002) 0.85
Unusual response to second-line single-agent gemcitabine in locally advanced primary leiomyosarcoma of the lung: a case report. J Chemother (2003) 0.85
Update on capecitabine alone and in combination regimens in colorectal cancer patients. Cancer Treat Rev (2010) 0.85
Characterization of a serum protein pattern from NSCLC patients treated with Gefitinib. Clin Biochem (2011) 0.85
Influence of GBV-C infection on the endogenous activation of the IFN system in HIV-1 co-infected patients. Cell Mol Biol (Noisy-le-grand) (2006) 0.84
Castration-resistant prostate cancer: targeted therapies. Chemotherapy (2011) 0.84
A randomised factorial trial of sequential doxorubicin and CMF vs CMF and chemotherapy alone vs chemotherapy followed by goserelin plus tamoxifen as adjuvant treatment of node-positive breast cancer. Br J Cancer (2005) 0.84
Development of a lipid-rich, soft plaque in rabbits, monitored by histology and intravascular ultrasound. Atherosclerosis (2001) 0.84
[Indications and preliminary results of diagnostic laparotomy in various types of malignant lymphoma]. Tumori (1972) 0.83
Solitary plasmacytoma of bone and extramedullary plasmacytoma: two different nosological entities? Tumori (1994) 0.83
Ability of peripheral blood mononuclear cells to activate interferon response in vitro is predictive of virological response in HCV patients. J Biol Regul Homeost Agents (2008) 0.83
Combination chemotherapy with DTIC (NSC-45388) in advanced malignant melanoma, soft tissue sarcomas, and Hodgkin's disease. Cancer Treat Rep (1976) 0.83
Combined chemotherapy (MOPP or ABVD)-radiotherapy approach in advanced Hodgkin's disease. Cancer Treat Rep (1977) 0.83
Combination chemotherapy with adriamycin (NSC-123127) in metastatic mammary carcinoma. Cancer Chemother Rep (1974) 0.83
Phase II trial of oral vinorelbine in combination with cisplatin followed by consolidation therapy with oral vinorelbine in advanced NSCLC. Lung Cancer (2004) 0.83
Subcutaneous recombinant interleukin-2 plus chemotherapy with cisplatin and dacarbazine in metastatic melanoma. Eur J Cancer (1996) 0.83
[Response and survival after sequential monochemotherapy in malignant lymphocytic and histocytic lymphoma]. Tumori (1973) 0.82
Revertant and potentiating activity of lonidamine in patients with ovarian cancer previously treated with platinum. J Clin Oncol (1997) 0.82